Exhibit 99.1 DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights Minneapolis, Minnesota – August 12, 2025 (Business Wire) – DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today provided a business update and reported financial results for the second quarter ended June 30, 2025. Management will host a conference ...